Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Dr. Davids Discusses Findings From DUO Study in CLL

January 8th 2019

Matthew S. Davids, MD, MMSc, associate director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute, discusses updated findings from the DUO study in patients with chronic lymphocytic leukemia.

Crossover to Duvelisib Feasible in Patients With CLL

January 8th 2019

Matthew S. Davids, MD, MMSc, discusses the clinical implications of the DUO trial in patients with chronic lymphocytic leukemia.

Time-Limited Therapy With Drug Cessation Feasible in CLL

January 5th 2019

John F. Seymour, MBBS, PhD, discusses the clinical implications of the MURANO trial and highlights the feasibility for time-limited therapy and its benefits for patients with chronic lymphocytic leukemia.

Standardizing MRD Testing for CLL

January 4th 2019

Take-Home Messages From ASH 2018 in CLL

January 4th 2019

CAR T-Cell Therapy for CLL

January 4th 2019

Duvelisib for Relapsed/Refractory CLL

January 4th 2019

Resistance to Ibrutinib in CLL

January 4th 2019

Resistance to Venetoclax in CLL

January 4th 2019

CD20-Targeted Antibodies With Novel Agents for CLL

January 4th 2019

Toxicity Management With Venetoclax for CLL

January 4th 2019

Venetoclax + Rituximab in Relapsed CLL

January 4th 2019

Real-World Data for CLL

January 4th 2019

Emerging BTK Inhibitors for CLL

January 4th 2019

Prognostic Factors in CLL

January 4th 2019

Novel Combination Therapies for CLL

January 4th 2019

Ibrutinib Versus FCR for Younger Patients With CLL

January 4th 2019

First-Line Therapy for Older Patients With CLL

January 4th 2019

Dr. Lamanna Discusses the MURANO Trial in CLL

January 2nd 2019

Nicole Lamanna, MD, associate professor of medicine, Hematologic Malignancies Section, Division of Hematology/Oncology, NewYork-Presbyterian/Columbia University Medical Center, discusses the MURANO trial in patients with chronic lymphocytic leukemia.

Fixed-Duration Venetoclax Triplet Active in CLL

January 1st 2019

Kerry A. Rogers, MD, discusses phase II findings of a trial with obinutuzumab, ibrutinib, and venetoclax and the future of dose-limited regimens in chronic lymphocytic leukemia.